Relay Therapeutics Inc (NASDAQ: RLAY) is -23.54% lower on its value in year-to-date trading and has touched a low of $1.77 and a high of $10.72 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The RLAY stock was last observed hovering at around $3.32 in the last trading session, with the day’s loss setting it -0.17%.
Currently trading at $3.15, the stock is 9.66% and 4.49% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 5.61 million and changing -5.12% at the moment leaves the stock -39.04% off its SMA200. RLAY registered -55.51% loss for a year compared to 6-month loss of -44.10%.
The stock witnessed a 57.50% gain in the last 1 month and extending the period to 3 months gives it a -31.97%, and is 1.61% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.49% over the week and 10.90% over the month.
Relay Therapeutics Inc (RLAY) has around 261 employees, a market worth around $569.20M and $7.68M in sales. Profit margin for the company is -4341.53%. Distance from 52-week low is 77.46% and -70.62% from its 52-week high. The company has generated returns on investments over the last 12 months (-43.73%).
The EPS is expected to grow by 14.76% this year.
Relay Therapeutics Inc (RLAY) Top Institutional Holders
The shares outstanding are 170.48M, and float is at 128.57M with Short Float at 14.28%.
The top institutional shareholder in the company is SB INVESTMENT ADVISERS (UK) LTD with over 27.9 million shares valued at $181.94 million. The investor’s holdings represent 21.0093% of the RLAY Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 11.7 million shares valued at $76.32 million to account for 8.8125 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 10.54 million shares representing 7.9375% and valued at over $68.74 million, while CASDIN CAPITAL, LLC holds 6.3608 of the shares totaling 8.45 million with a market value of $55.08 million.
Relay Therapeutics Inc (RLAY) Insider Activity
The most recent transaction is an insider sale by Rahmer Peter, the company’s. SEC filings show that Rahmer Peter sold 10,739 shares of the company’s common stock on Apr 30 ’25 at a price of $3.00 per share for a total of $32217.0. Following the sale, the insider now owns 0.39 million shares.
Relay Therapeutics Inc disclosed in a document filed with the SEC on Apr 28 ’25 that Rahmer Peter sold a total of 1,364 shares of the company’s common stock. The trade occurred on Apr 28 ’25 and was made at $3.17 per share for $4324.0. Following the transaction, the insider now directly holds 0.4 million shares of the RLAY stock.
Still, SEC filings show that on Apr 30 ’25, Catinazzo Thomas (Chief Financial Officer) disposed off 12,943 shares at an average price of $3.00 for $38829.0. The insider now directly holds 355,376 shares of Relay Therapeutics Inc (RLAY).
